Castle Creek Biosciences chair Jeff Aronin

Scoop: Af­ter pulling IPO am­bi­tions last De­cem­ber, Jeff Aron­in's Cas­tle Creek turns to pri­vate back­ers

Jeff Aronin’s cell and gene ther­a­py biotech Cas­tle Creek Bio­sciences has raised $112 mil­lion in eq­ui­ty, End­points News has learned.

The Ex­ton, PA, biotech se­cured …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.